Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Terns Pharmaceuticals (Nasdaq: TERN) has appointed Andrew Gengos as Chief Financial Officer, effective immediately. Gengos brings 25 years of leadership experience in biotech and life sciences to the clinical-stage biopharmaceutical company.
Gengos most recently served as CFO of Athira Pharma and previously as Chief Business Officer at Cyteir Therapeutics, where he led the company's IPO finance team. His experience includes CEO roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, and eight years as VP of Strategy and Corporate Development at Amgen.
The appointment comes as Terns, which focuses on developing small-molecule product candidates for oncology and obesity, anticipates clinical readouts later this year. Gengos holds an MBA from UCLA Anderson School of Management and a BS in Chemical Engineering from MIT.
Terns Pharmaceuticals (Nasdaq: TERN) ha nominato Andrew Gengos come Chief Financial Officer, con effetto immediato. Gengos porta con sé 25 anni di esperienza dirigenziale nel settore biotech e delle scienze della vita per la società biofarmaceutica in fase clinica.
Recentemente, Gengos ha ricoperto il ruolo di CFO presso Athira Pharma e in precedenza è stato Chief Business Officer di Cyteir Therapeutics, dove ha guidato il team finanziario per l'IPO dell'azienda. La sua esperienza include ruoli di CEO in ImmunoCellular Therapeutics e Neuraltus Pharmaceuticals, e otto anni come VP di Strategia e Sviluppo Aziendale in Amgen.
La nomina arriva mentre Terns, che si concentra sullo sviluppo di candidati a piccole molecole per oncologia e obesità, prevede risultati clinici entro la fine dell'anno. Gengos ha conseguito un MBA presso la UCLA Anderson School of Management e una laurea in Ingegneria Chimica al MIT.
Terns Pharmaceuticals (Nasdaq: TERN) ha nombrado a Andrew Gengos como Director Financiero, con efecto inmediato. Gengos aporta 25 años de experiencia en liderazgo en biotecnología y ciencias de la vida a la empresa biofarmacéutica en etapa clínica.
Recientemente, Gengos se desempeñó como CFO de Athira Pharma y anteriormente fue Director de Negocios en Cyteir Therapeutics, donde lideró el equipo financiero de la OPI de la empresa. Su experiencia incluye roles de CEO en ImmunoCellular Therapeutics y Neuraltus Pharmaceuticals, y ocho años como VP de Estrategia y Desarrollo Corporativo en Amgen.
La nombramiento se produce mientras Terns, que se centra en el desarrollo de candidatos a moléculas pequeñas para oncología y obesidad, anticipa resultados clínicos para finales de este año. Gengos tiene un MBA de la UCLA Anderson School of Management y una licenciatura en Ingeniería Química del MIT.
Terns Pharmaceuticals (Nasdaq: TERN)은 Andrew Gengos를 최고 재무 책임자(CFO)로 즉시 임명했습니다. Gengos는 임상 단계의 생명공학 회사에 25년의 리더십 경험을 제공합니다.
Gengos는 최근 Athira Pharma의 CFO로 재직했으며, 이전에는 Cyteir Therapeutics의 최고 사업 책임자로서 회사의 IPO 금융 팀을 이끌었습니다. 그의 경험에는 ImmunoCellular Therapeutics와 Neuraltus Pharmaceuticals의 CEO 역할이 포함되며, Amgen에서 전략 및 기업 개발 부사장으로 8년을 보냈습니다.
이번 임명은 Terns가 종양학 및 비만을 위한 소분자 제품 후보 개발에 집중하고 있으며, 올해 말 임상 결과를 예상하고 있는 가운데 이루어졌습니다. Gengos는 UCLA Anderson School of Management에서 MBA를, MIT에서 화학 공학 학사 학위를 받았습니다.
Terns Pharmaceuticals (Nasdaq: TERN) a nommé Andrew Gengos au poste de directeur financier, avec effet immédiat. Gengos apporte 25 ans d'expérience en leadership dans le secteur de la biotechnologie et des sciences de la vie à l'entreprise biopharmaceutique en phase clinique.
Récemment, Gengos a été CFO d'Athira Pharma et auparavant directeur des affaires chez Cyteir Therapeutics, où il a dirigé l'équipe financière pour l'introduction en bourse de l'entreprise. Son expérience comprend des rôles de PDG chez ImmunoCellular Therapeutics et Neuraltus Pharmaceuticals, ainsi que huit ans en tant que VP de la stratégie et du développement d'entreprise chez Amgen.
Cette nomination intervient alors que Terns, qui se concentre sur le développement de candidats à petites molécules pour l'oncologie et l'obésité, prévoit des résultats cliniques plus tard cette année. Gengos détient un MBA de la UCLA Anderson School of Management et un diplôme en ingénierie chimique du MIT.
Terns Pharmaceuticals (Nasdaq: TERN) hat Andrew Gengos mit sofortiger Wirkung zum Chief Financial Officer ernannt. Gengos bringt 25 Jahre Führungserfahrung in der Biotechnologie und Lebenswissenschaften in das klinische biopharmazeutische Unternehmen ein.
Zuletzt war Gengos CFO von Athira Pharma und zuvor Chief Business Officer bei Cyteir Therapeutics, wo er das Finanzteam für den Börsengang des Unternehmens leitete. Zu seinen Erfahrungen gehören CEO-Positionen bei ImmunoCellular Therapeutics und Neuraltus Pharmaceuticals sowie acht Jahre als VP für Strategie und Unternehmensentwicklung bei Amgen.
Die Ernennung erfolgt, während Terns, das sich auf die Entwicklung von kleinen Molekülkandidaten für Onkologie und Adipositas konzentriert, klinische Ergebnisse für später in diesem Jahr erwartet. Gengos hat einen MBA von der UCLA Anderson School of Management und einen Bachelor-Abschluss in Chemieingenieurwesen vom MIT.
- Appointment of experienced CFO with 25 years of biotech industry leadership
- New CFO has successful track record in taking companies public
- Strategic timing with clinical readouts expected later this year
- None.
Seasoned public company CFO with 25 years of leadership experience in biotech
FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately.
“We are delighted to have Andrew join the Terns’ team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew’s contributions as we continue to advance our mission to transform patients’ lives through the development of new medicines that have a valuable, enduring impact on human health,” said Amy Burroughs, chief executive officer of Terns.
“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts later this year,” said Mr. Gengos. “I look forward to working with the talented Terns’ leadership team to build on the Company’s strong financial foundation and drive continued success in bringing new treatment options to patients battling serious diseases, including oncology and obesity.”
Mr. Gengos is a seasoned finance and corporate strategy executive with 25 years of experience, successfully leading teams in the life sciences and biotechnology industry. Most recently, he served as the chief financial officer of Athira Pharma, Inc. Prior to that, Mr. Gengos was chief business officer at Cyteir Therapeutics, where he led the finance team that took the company public. In addition, Mr. Gengos held chief executive officer roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, where he provided strategic and financial leadership across multiple therapeutic areas, including oncology and neurodegenerative disease. Earlier, Mr. Gengos was vice president of strategy and corporate development at Amgen for eight years. Mr. Gengos started his career at Morgan Stanley before moving on to McKinsey & Co., where he advanced from associate to senior engagement manager. Mr. Gengos holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
Who is the new CFO of Terns Pharmaceuticals (TERN) as of February 2025?
What is Andrew Gengos's most recent position before joining TERN?
What major clinical developments are expected for TERN in 2025?
What is Andrew Gengos's experience with taking companies public?
How long did Andrew Gengos work at Amgen and in what role?
